A previously healthy 45-year-old Korean-born man presented with pleuritic chest pain and a dry cough in February 2005. His symptoms began one week after returning home to Toronto, Ontario, following a trip to northern Mexico, where he had spent several days in a large city attending meetings. He denied having fever, rash or arthralgia. His chest pain and cough were initially managed symptomatically with an analgesic and a cough supressant. However, the symptoms persisted and after one week, he was referred to a respirologist for further investigation and management. His physical examination was normal. His complete blood count revealed marked eosinophilia (6.0×10 9 /L) and his chest radiograph documented a right lung infiltrate. A computed tomography scan confirmed consolidation in the right upper lobe and revealed centrilobular nodules in a tree-in-bud pattern, right hilar and mediastinal lymphadenopathy and small nodules (less than 0.5 mm) scattered throughout both lungs.
DIAGNOSIS
After five days of incubation, cultures on blood agar plates grew a white mould. Microscopic examination of a lactophenol aniline blue preparation revealed 'barrel-shaped' mycelial arthroconidia, characteristic of the highly pathogenic fungus Coccidioides (Figure 1 ). The samples were forwarded to a reference laboratory and molecular testing confirmed the presence of Coccidioides species.
The diagnosis of coccidioidomycosis was made three weeks after symptom onset, by which time the patient's pleuritic chest pain had resolved and his chest x-ray had improved. Coccidioides serology, by the complement fixation test, was positive at a titre of 1:4. Given the patient's spontaneous clinical resolution, the decision was made to withhold antifungal agents.
At follow-up six months later, he remained asymptomatic. The chest radiograph changes and eosinophilia had resolved; his serology remained unchanged at a titre of 1:4.
DISCUSSION
Coccidioidomycosis is an invasive fungal infection caused by the inhalation of the arthroconidia (spores) of the dimorphic fungus Coccidioides. Although Coccidioides species (Coccidioides immitis and Coccidioides posadasii) are found in a geographically restricted habitat, infection can manifest as illness in returning travellers and is increasingly diagnosed in nonendemic areas (1) . Although intense exposure to dust or soil is a risk factor, most infections occur without such an exposure history.
C immitis is endemic to regions in the southwestern United States -common destinations for Canadian snowbirds.
C posadasii is more widespread and found in regions of Mexico and South and Central America with similar climate and soil conditions. The two species have otherwise indistinguishable clinical features (1) .
Following inhalation, the tiny arthroconidia (3 μm to 5 μm) can travel to the alveoli, where they undergo a dimorphic shift and develop into large spherules (40 μm to 100 μm) filled with endospores. These spherules incite a granulomatous reaction and a strong Th1-type, cell-mediated immune response is required to control the infection. Th2-type immune responses may confer susceptibility to dissemination. Peripheral eosinophilia, associated with Th2 responses, has been suggested to be a marker of disseminated disease (2). However, eosinophilia may simply represent a hypersensitivity reaction (3).
The majority of individuals infected with Coccidioides infection remain asymptomatic (4). Fewer than 50% develop clinical illness, most commonly a respiratory illness, mimicking typical community-acquired pneumonia. Approximately 50% have associated peripheral eosinophilia and 25% develop erythema nodosum which are useful diagnostic clues (5) .
The primary illness is typically self-limited. Fewer than 5% of individuals develop progressive or persistent pulmonary disease, and fewer than 1% develop extrapulmonary complications. However, the risk of disseminated disease is high, up to 50%, in immunocompromised patients. Typical sites of dissemination include the skin, bones and the meninges; however, any organ can be involved. Disseminated disease may coincide with symptoms of primary pulmonary infection or may occur weeks to months later. Coccidioides spherules can persist within granulomas and can disseminate in the setting of future immunosuppression following a period of latency (6) . Of note, approximately 50% of Coccidioides infections in patients with AIDS are diagnosed outside of endemic regions (7) .
Laboratory diagnosis of Coccidioides can be made by the direct visualization of the characteristic arthroconidia or spherules in sputum samples or tissue biopsies. However, direct visualization is only 40% sensitive compared with culture (8) .
Coccidioides grows readily on most media within five days. The definitive identification of Coccidioides from culture typically requires the use of exoantigen tests or DNA probes.
Due to its virulence and potential for aerosol, the microbiology laboratory should be advised of the possibility of Coccidioides so that proper precautions can be taken (biosafety level 3 practices).
Diagnosis is frequently made by serology. Detection of complement-fixing antibody has good specificity, and high titres (greater than 1:16) are markers for increased risk of complications (9) .
Updated treatment guidelines for coccidioidomycosis have recently been published (10) . In general, given the wide spectrum of disease, treatment is individualized according to the extent of infection and risk factors for dissemination. Although recommendations vary from observation alone for uncomplicated pneumonia to life-long systemic antifungals and consideration of intrathecal amphotericin B for meningitis, all patients require clinical follow-up after primary infection.
The present case highlights the need to remember this re-emerging fungal pathogen as a cause of eosinophilic pneumonia and an important cause of illness in returning travellers.
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